Cernostics
Biotechnology company delivering spatial biology solutions to the clinic, focused on precision diagnostics for Barrett's esophagus and early cancer detection.
Website
https://www.cernostics.comLocation
Pittsburgh, Pennsylvania, USA
Founded
2011
Investors
1
Categories
spatial-biology, pathology, diagnostics, precision-medicine, biotech, barretts-esophagus
Notes
Cernostics is a biotechnology company focused on delivering spatial biology solutions to clinical practice. The company has developed TissueCypher®, an FDA-cleared tissue systems pathology test for Barrett's esophagus that helps identify patients at risk of progressing to esophageal cancer.
The company's technology uses spatial biology and artificial intelligence to analyze tissue samples, providing objective, reproducible diagnostic information that helps clinicians make more informed treatment decisions.
Team
- Michael Gerdes, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/michaelgerdes
- Robert Kim - Co-founder & Chief Scientific Officer
Additional Research Findings
- TissueCypher® test for Barrett's esophagus
- FDA-cleared diagnostic test
- Spatial biology and AI-powered diagnostics
- Focus on early cancer detection
- Pittsburgh, Pennsylvania headquarters
- Carnegie Mellon University spinout
- Precision diagnostics for GI conditions
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |